Modern concepts of inflammatory diseases of the pelvic organs

Pelvic inflammatory disease is a collective term that includes infectious inflammatory diseases of the upper genital tract of women with the involvement of the uterine (fallopian tubes), ovaries and surrounding tissues. The incidence of inflammatory diseases of the pelvic organs in the world is growing every year, with a particularly clear increase in the incidence in the age groups of 18-24 years (1,4 times) and 25-29 years (1,8 times) over the past decade, which can be a consequence of the early onset of sexual activity. The spectrum of pathogens that cause inflammation of the female genital organs is quite wide and includes both bacteria and sexually transmitted pathogens, which, if there are several ways of infection, increases the risk of pelvic organ disease. The negative effect of the immune response on intracellular metabolism and the functions of the corresponding organs and tissues has been proven. As a result, the clinical effect of treatment decreases and causes the progression and relapses of the disease, and it becomes necessary to search for new ways of prevention and treatment. The importance of inflammatory diseases of the pelvic organs is primarily due to the fact that this group of diseases leads to violations of the reproductive function of women, for example, it can cause the development of infertility in marriage, in particular, tubal and/or peritoneal factors; organic complications such as chronic pelvic pain syndrome. In 15-20% of patients, an acute inflammatory process turns into a chronic one with the development of an adhesive process. Salpingitis and salpingo-oophoritis can lead to the development of adhesive pelvioperitonitis and, as a possible consequence, to the appearance of tubal-peritoneal factor of infertility. For example, women with ascending chlamydial infection with pelvic inflammatory disease may develop Fitz – Hugh – Curtis syndrome (perihepatitis). This article describes the current understanding of PID, as well as the advantage of the drug levofloxacin in the treatment of this group of diseases.

1. Bezbakh I. V. The use of structural resonance therapy in the rehabilitation treatment of patients with chronic salpingo-oophort // Zhurnal Rossiyskogo obshchestva akusherov-ginekologov. 2006; 3: 26-28.

2. Medvedev B. I. i dr. Inflammatory diseases of the uterus and appendages. Chelyabinsk, 2001. 278.

3. Strizhakov A. N. i dr. Genital infections. M.: Izd. dom «Dinastiya», 2003. P. 134.

4. Krasnopol'skiy V. I. i dr. Purulent-septic complications in obstetrics and gynecology: pathogenesis, diagnosis and treatment tactics // Rossiyskiy vestnik akushera-ginekologa. 2007; 1 (7): 63-68.

5. DeCherni A. Kh., Natan L. Obstetrics and gynecology: textbook. M.: MED-press-inform, 2009. p. 216-217.

6. Sauleva T. Modern views on the etiology, pathogenesis, diagnosis and treatment of bacterial vaginosis as a sexually transmitted disease // Bicnik mor'koi meditsini. 2000; 3: 28-32.

7. Davis R., Bryson H. M., Levofloxacin: a review of its antibacterial activity, farmacokinetics and therapeutic efficasy // Drags. 1994; 47; 677-700.

8. Cooper I., Isbell D. J., Kruszinsky J. A. et al. Comparative in vitro activity of L-ofloxacin and FK037 to other agents against 10,040 fresh clinical isolates // Int J Antimicrob Agents. 1996; 6: 201-211.

9. DeAbate C. A., Russel M., McElvaine P. et al. Safety and efficasy of levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronhitis // Respir Care. 1997; 42: 206-213.

10. Levison M. E., Bush L. M. Peritonitis and other intra-abdominal infections. 1995.

11. Guay D. R. P. Implications of quinolones pharmacocinetic drag interactions // Hosp Pharm. 1997; 32: 677-690.

12. Fish D. N. Fluoroquinolones adverse effects and drag interactions // Pharmacotherapy. 2002; 21 (10pt2); 2535-2572.

13. Lipsky B. A., Baker C. A. Fluoroquinolones toxiticy prophil; a review focusing on newer agents // Clin Infect Dis. 1999; 28: 352-364.

14. Mukimz-Oda T. M., Khodzhamurodova D. A. Inflammatory diseases of the pelvic organs and prolonged use of intrauterine contraception (clinical case) // Meditsinskiy alfavit. 2019. T. 2. № 14 (389). S. 47-51. DOI 10.33667/2078-5631-2019-2-14(389)-47-51.

15. Russian Society of Obstetricians and Gynecologists. Clinical recommendations. Inflammatory diseases of the female pelvic organs. 2021.

16. Curry A., Williams T., Penny M. L. Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention // Am Fam Physician. 2019; 100 (6): 357-364. PMID: 31524362.

17. Ravel J., Moreno I., Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease // Am J Obstet Gynecol. 2021; 224 (3): 251-257. DOI: 10.1016/j.ajog.2020.10.019. Epub 2020 Oct 19. PMID: 33091407.

18. Savaris R. F., Fuhrich D. G., Maissiat J., Duarte R. V., Ross J. Antibiotic therapy for pelvic inflammatory disease // Cochrane Database Syst Rev. 2020; 8 (8): CD010285. DOI: 10.1002/14651858.CD010285.pub3. PMID: 32820536; PMCID: PMC8094882.

19. Dobrokhotova Yu. E., Filatova L. A., Grishin I. I. The results of the use of bovhyaluronidase azoximer in the complex therapy of inflammatory diseases of the pelvic organs // RMJ. 2018; 2-1 (26): 19-22.